title: Anti-thymocyte globulin treatment of a patient for paroxysmal nocturnal haemoglobinuria-aplastic anaemia syndrome: complement activation and transient decrease of the PNH clone.
abstract: Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired clonal stem cell disorder resulting in insufficient and defective haematopoesis associated frequently with aplastic anaemia (AA). A deficiency of the glycosyl phosphatidylinositol (GPI)-anchored complement activation regulatory proteins CD55 and CD59 is responsible for an increased sensitivity of erythrocytes to complement attack leading to chronic intravascular haemolysis with haemoglobinuria. In this study we investigated the effects of complement activation caused by anti-thymocyte globulin (ATG) treatment on the PNH clone in a patient affected with the PNH/AA-syndrome. Fluid phase complement components C3, C4, C6 and terminal complement complex (TCC) were assayed by ELISA. CD55, CD59 and cell-associated TCC were monitored by flow cytometry. ATG treatment resulted in profound systemic complement activation which led to a decrease in the levels of native C3 and C4 to 65% and 40%, respectively, of the original levels on day 5 and of C6 and TCC to 61% and 23%, respectively, on day 10. A return to pre-treatment levels was observed for C3 by day 15, for C6 by day 30 and for C4 by day 90. Flow cytometry revealed that the deficiency in the GPI-anchored protein was restricted to granulocytes, while lymphocytes remained unaffected. Cell-bound TCC increased by 1.67-fold and 2.37-fold on day 5 and day 10, respectively, decreasing to 1.40-fold and 1.30-fold on day 15 and day 30, respectively. The percentage of PNH granulocytes as identified by the absence of the CD55- and CD59-antigens exhibited a temporary decrease from 72% on day 0 to 65% on day 5 and 59% on day 10 and returned thereafter to the original percentage of 70% by day 15 and exceeding this level to 76% on day 30 and 79% on day 90. We report profound activation of the classical pathway of the complement cascade and the terminal complement complex by the globulin leading to a transient decrease of the PNH clone, presumably due to subsequent lysis of the PNH cells devoid of complement regulatory proteins.
authors.affiliation: Department of Medicine, University of Innsbruck, Austria.
authors.forename: C F
authors.initials: CF
authors.lastname: Ebenbichler
authors.forename: R
authors.initials: R
authors.lastname: Würzner
authors.forename: A D
authors.initials: AD
authors.lastname: Sandhofer
authors.forename: D
authors.initials: D
authors.lastname: Niederwieser
authors.forename: M P
authors.initials: MP
authors.lastname: Dierich
authors.forename: J R
authors.initials: JR
authors.lastname: Patsch
mesh_terms: D000741:Anemia, Aplastic / Q000097:blood* / Q000276:immunology / Q000628:therapy*; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D003167:Complement Activation / Q000276:immunology*; D005434:Flow Cytometry; D006098:Granulocytes / Q000473:pathology; D006457:Hemoglobinuria, Paroxysmal / Q000097:blood* / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007958:Leukocyte Count; D009190:Myelodysplastic Syndromes / Q000097:blood* / Q000276:immunology / Q000628:therapy*
chemical_list: D000961:Antilymphocyte Serum